How do I buy Axogen, Inc. (AXGN) stock?

Buying Axogen, Inc. (AXGN) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "AXGN", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy AXGN by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

What is the minimum investment for AXGN on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Axogen, Inc. from just $1. A small budget shouldn't stop you from building a US stock portfolio.

Does Axogen, Inc. (AXGN) pay dividends?

At the moment, Axogen, Inc. (AXGN) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track AXGN's performance via the price chart in the Gotrade app.

Is buying AXGN on Gotrade safe and legal?

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

What are the market hours to buy AXGN?

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too. The market is closed on US public holidays. The Gotrade app shows whether the market is open.

How do I tell if AXGN is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Axogen, Inc. (AXGN) Stock Price: Nov 11 Close $58.63

Latest news

Zacks Investment Research

News tone: automated (AI) classification of the article's content, not a price prediction.

About Axogen, Inc.

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

SectorHealthcare

IndustryMedical Devices

Employees622

CEOMr. Michael D. Dale

IPO DateMar 27, 1990

HeadquartersAlachua, FL

Key Executives

Name	Title	Year Born
Mr. Michael D. Dale	President, CEO & Director	1960
Ms. Lindsey Hartley CPA	Chief Financial Officer	—
Mr. Erick DeVinney	Chief Scientific Officer	1976
Mr. Marc A. Began	Executive VP, General Counsel, Secretary & Chief Compliance Officer	1968
Mr. Jens Schroeder Kemp	Chief Marketing Officer	1977
Mr. Craig A. Swandal	Senior Vice President of Operations	1961
Mr. Harold D. Tamayo M.B.A.	Vice President of Finance & Investor Relations	—
Dr. Ivica Ducic M.D., Ph.D.	Chief Medical Officer	—
Ms. Doris Quackenbush	Chief Revenue Officer	—
Mr. Rick Ditto	Vice President of Global Health Economics, Reimbursement & Policy	—

Fundamentals

Valuation

Price-to-sales ratio16.23

Price-to-book value6.13

PEG ratio99.04

Profitability

Return on Equity-18.00%

Return on Assets-13.00%

Return on Sales-12.00%

Gross margin (latest quarter)74.81%

EBITDA$-20.30M

Trading

Average volume1,826,964

Dividend

Ex dividend date27 Jan 2010

Source: third-party data provider, as of November 13, 2026

Technical indicators

RSI 14: 79.36
MACD 12/26/9: 3.62
EMA 9 of MACD: 2.27
MACD histogram: 1.34
SMA 50: $42.95; Price above SMA 50
EMA 50: $44.24; Price above EMA 50
SMA 200: $40.31; Price above SMA 200
EMA 200: $39.51; Price above EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst views

8 analyst ratings

Third-party analyst opinion, not a recommendation from Gotrade.

Analyst consensus:Buy

100% Buy

0% Hold

0% Sell

Analyst price target

Low: $52.00
Average: $56.63
High: $60.00

Barclays

Christopher Pasquale

Buy

Target price

$60.00

Raymond James

Jayson Bedford

Buy

Target price

$53.00

Leerink Partners

Mike Kratky

Buy

Target price

$56.00

HC Wainwright & Co.

Yi Chen

Buy

Target price

$56.00

B of A Securities

Travis Steed

Buy

Target price

$52.00

Wells Fargo

Larry Biegelsen

Buy

Target price

$56.00

Canaccord Genuity

Caitlin Roberts

Buy

Target price

$60.00

Truist Securities

Ravi Misra

Buy

Target price

$60.00

Seasonality

Monthly price change (%)

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2021											-18.1	-0.6
2022	-12.7	+8.6	-12.4	-11.3	+28.9	-11.8	+14.1	-3.9	+27.1	-5.7	-2.0	-9.5
2023	-4.1	-11.2	+15.8	-4.0	-8.3	+5.7	-2.4	-26.4	-20.6	-24.8	+81.4	-0.7
2024	+39.9	+8.3	-24.5	-19.4	+4.1	+6.2	+13.9	+61.2	+6.6	-2.2	-0.4	+13.2
2025	+11.0	+11.7	-4.1	-8.6	-33.9	-1.1	+19.4	+27.4	+13.6	+24.3	+23.2	+14.7
2026	+12.4	-9.4	+8.1	+28.6	-8.8	+19.3	-4.1	+11.0	-16.0	+23.7	+17.6

Compare stocks

AXGN

Buy AXGN

Market cap

$3.50B

-

Price / Earnings ratio

-95.20

-

Price / Sales ratio

16.23

-

Dividend yield

0.00%

-

Average volume

1,826,964

-

Earnings per share

$-0.65

-

Axogen, Inc. (AXGN) Stock

Key stats

Compare with AXGN

Recent news

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

AxoGen Q3 Earnings Call Highlights

AxoGen Q3 Earnings Call Highlights

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

GMED vs. AXGN: Which Stock Should Value Investors Buy Now?

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?

AxoGen Q3 Earnings Call Highlights

AxoGen Q3 Earnings Call Highlights

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth

GMED or AXGN: Which Is the Better Value Stock Right Now?

GMED or AXGN: Which Is the Better Value Stock Right Now?

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

Down 22.6% in 4 Weeks, Here's Why You Should You Buy the Dip in AxoGen (AXGN)

3 Emerging Biotech Stocks With Significant Upside Potential

3 Emerging Biotech Stocks With Significant Upside Potential

AxoGen Q2 Earnings Call Highlights

AxoGen Q2 Earnings Call Highlights

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

AxoGen (AXGN) Tops Q2 Earnings and Revenue Estimates

About Axogen, Inc.

Key Executives

Fundamentals

Valuation

Profitability

Trading

Dividend

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade